Morgan Stanley Resumes Abbott Labs (ABT) at Overweight
More News related to ABT
- Absolute Helps Police Break Possible Identity Theft Ring
- Absolute's Computrace Included in a Major Computer Manufacturer's Customer Care Program
- Johnson & Johnson's (JNJ) Wins $1.67B Patent Verdict Versus Abbott Laboratories (ABT)
- Absolute Software Exhibiting at National Education Computing Conference (NECC) 2009
- Abbott Hosts Conference Call for Second-Quarter Earnings
Morgan Stanley resumes coverage on Abbott Laboratories (NYSE: ABT) with an Overweight rating.
Abbott Laboratories engages in the development, manufacture, and sale of health care products worldwide.
Related Categories
New CoverageStocks Mentioned
-21.60Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
